Skip Ribbon Commands
Skip to main content
Menu

Prof Lam Su Ping Carolyn

Prof Carolyn Lam from National Heart Centre Singapore

Prof Lam Su Ping Carolyn

​MBBS, PhD, MRCP, MS, FACC, FAMS, FESC

Senior Consultant

Specialty: Cardiology

Sub-specialties: Heart Failure

Conditions Treated by this Doctor:
General Cardiology, Heart Failure.

Clinical Appointments

  • Senior Consultant Department of Cardiology National Heart Centre SingaporeNational Heart Centre Singapore
  • Director of Women’s Heart Health National Heart Centre SingaporeNational Heart Centre Singapore

Academic Appointments

  • Research EXCO SingHealth Duke-NUS Cardiovascular Sciences Academic Clinical Programme

Profile

Professor Carolyn Lam is a Senior Consultant from the Department of Cardiology at the National Heart Centre Singapore (NHCS). She is also the Director of the Women’s Heart Health at NHCS.

Her clinical sub-specialty is heart failure, and she is recognized globally for her expertise in heart failure with preserved ejection fraction (HFpEF). She also has expertise in women’s cardiovascular disease, hemodynamics, echocardiography, biomarkers and research clinical trials. She started the first Heart Failure with Preserved Ejection Fraction Programme and Women’s Heart Health Clinic in Singapore.

On the research front, Prof Lam is a Research EXCO member of the SingHealth Duke-NUS Cardiovascular Sciences Academic Clinical Programme; a Scientific Advisor to the Clinical Trials Coordinating Centre at SingHealth; an Affiliate Member of the SingHealth Duke-NUS Institute of Precision Medicine. She is also a Clinician Scientist and received the National Medical Research Council (NMRC) Clinician Scientist Award in 2010.

She is the Programme Lead of the Asian neTwork for Translational Research and Cardiovascular Trials (ATTRaCT) – an A*STAR Biomedical Research Council-funded research platform; and principal investigator of an ongoing nation-wide heart failure study in Singapore (the Singapore Heart Failure Outcomes and Phenotypes [SHOP] study), a multinational Asian study of heart failure across 11 Asian countries (Asian Sudden Cardiac Death in Heart Failure [ASIAN-HF] study). She serves as a consultant on several global advisory boards for cardiovascular disease, as a member of the Executive Committees of global heart failure trials, and as an Associate Editor for Circulation and European Journal of Heart Failure. 

Graduated from the Faculty of Medicine, National University of Singapore, Prof Lam completed advanced specialty training in Cardiology in Singapore, and pursued her Research Fellowship at the Cardiorenal Laboratory, Heart Failure Fellowship at the Division of Cardiovascular Diseases, and Advanced Cardiology and Master of Biomedical Sciences at Mayo Clinic, Rochester MN. She further received training in clinical and genetic epidemiology at the Framingham Heart Study in Boston, MA, graduated from the Stanford Executive Programme and obtained her PhD at University Medical Centre Groningen.

Prof Lam was also awarded the L’Oreal Women In Science Award (2012) for her work in heart failure and women’s cardiovascular disease respectively, was named an InterAcademy Medical Panel Young Physician Leader at the World Health Summit in Berlin (2012), won the award for the Junior Chamber International (JCI) Ten Outstanding Young Persons of the World for 2014 –Singapore (2014).

She is also heard weekly on the global podcast “Circulation On The Run” and seen regularly on television as the Resident Doctor of the health programme ‘Body and Soul’ by Mediacorp Singapore.

Education

  • Royal College of Physicians of Edinburgh Fellow of the Royal College of Physicians (FRCP), 2018​
  • University of Groningen, NLD PhD, 2016
  • Stanford Graduate School of Business, Stanford Executive Programme, 2015
  • Framingham Heart Study, MA, US, Fellowship (Clinical & Genetic Epidemiology), 2010
  • Mayo Clinic, Rochester MN, US, Master of Biomedical Science, 2009
  • Mayo Clinic, Rochester MN, US, Fellowship (Heart Failure & Advanced Cardiology), 2009
  • Ministry of Health, Singapore Specialist Accreditation (Cardiology), 2005
  • National University of Singapore, Bachelor of Medicine and Bachelor of Surgery (MBBS), 1998

Professional Appointments and Committee Memberships

  • ​Senior Consultant, Department of Cardiology, National Heart Centre Singapore
  • Director, Women's Heart Health, National Heart Centre Singapore
  • Director, Clinical Trials, National Heart Centre Singapore, to Apr 2020
  • Affiliate Member, SingHealth Duke-NUS Institute of Precision Medicine
  • Professor, Programme in Cardiovascular and Metabolic Disorders, Duke-NUS Medical School
  • Associate Editor, Circulation and European Journal of Heart Failure
  • Member of Expert Panel for the National Cardiovascular Data Registry PINNACLE and Diabetes Collaborative Registries
  • Member of the Scientific Committee of CVD-REAL global consortium, representing Asia Pacific 
  • Core Scientific Committee member (co-chairing with Mikhail Kosiborod and Kamlesh Khunti) leading the new DISCOVER global registry by Astra Zeneca
  • Steering Committee, Phase 2b study with vericiguat in patients with heart failure and preserved ejection fraction by Bayer Healthcare and Merck (Merck, Sharpe & Dohme outside of the US)
  • Chair, Abbott Laboratories Asia Pacific hsTnI Advisory Board
  • Chair, Astra Zeneca Advisory Board for HFpEF
  • Executive committee, Early phase trial in HFpEF (PROMIS-HFpEF trial) by Astra Zeneca
  • Global medical advisory board, Boston Scientific
  • Executive committee, Multiple Cardiac Sensors for Management of Heart Failure (MANAGE-HF trial) by Boston Scientific
  • International scientific advisory board, Corvia Medical
  • Global cardiovascular advisory board, Boehringer Ingelheim
  • Scientific excellence committee, Global phase 3 trial of Empagliflozin in HFrEF and HFpEF (EMPEROR trial) by Boehringer Ingelheim
  • Global advisory board, Vifor Pharma Iron Core
  • Global advisory board, Vifor Pharma Iron Deficiency In Heart Failure
  • Global Hyperkalemia Council by Vifor Pharma
  • Steering committee, Vifor Pharma Headquarters Global Education Programme
  • Executive steering committee, Phase 3 heart failure trial of vericiguat (VICTORIA) by academic-pharmaceutical industry partnership between the Canadian VIGOUR center at University of Alberta, Duke Clinical Research Institute, Bayer and Merck
  • Executive committee, Randomised Double-blind Event-driven Multicentre Study Comparing the Efficacy and Safety of Oral Rivaroxaban With Placebo for Reducing the Risk of Death Myocardial Infarction or Stroke in Subjects With Heart Failure and Significant Coronary Artery Disease Following an Exacerbation of Heart Failure (COMMANDER HF Trial) by Janssen R&D
  • Consultant, Bayer HealthCare Pharmaceuticals Pharma Management Team on Heart Failure & Bayer’s Portfolio
  • Executive committee, Effect of LCZ696 in heart failure with preserved ejection fraction (PARAGON trial)
  • Executive committee, Serelaxin in Asian AHF patients (RELAX-ASIA) trial by Novartis
  • Executive committee, SOluble Guanylate Cyclase stimulatoR in heArT failurE patientS (SOCRATES-PRESERVED trial)
  • Steering committee, Global HF registry by Novartis (REPORT-HF study)
  • Participant of The World Heart Federation (WHF) Roadmaps Heart Failure in Adults, Writing Committee (AHFWC), 2017
  • Lancet Commission on Cardiovascular Disease in Women, 2017
  • International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Task Force on Clinical Applications of Cardiac Bio-Markers, 2017 
  • Writing group for the updated Heart Failure Association/ European Society of Cardiology Consensus Document for the Diagnosis of Heart Failure with Preserved Ejection Fraction, 2015
  • Working Group for Heart Failure Outcomes, International Consortium for Health Outcomes Measurement, 2015
  • European Atherosclerosis Society Familial Hypercholesterolemia Studies Collaboration, 2015

Awards

  • Singapore Health Quality Award 2018 – Outstanding & Commendable service for the period of April 2016 to March 2017, 2018
  • ESC Grants to attend Women Transforming Leadership Programme at Oxford University, 2017   
  • LEAP Award – EXCELLENCE (For ‘Honours’ Grade) for ACP Mentor, 2017 
  • Rosalind Franklin Fellowship Award, 2015
  • Junior Chamber International (JCI) Ten Outstanding Young Persons of the World for 2014 – Singapore Honouree Winner for Medical Innovation, 2014
  • National Medical Research Council Clinician Scientist Award (Senior Investigator category), 2013
  • Singapore Women’s Weekly Great Women Of Our Times (Winner), 2013
  • L’Oreal Women In Science, 2012
  • InterAcademy Medical Panel Young Physician Leader (World Health Summit, Berlin), 2012
  • Investigational Medicine Unit Bridging Fund Award, 2012
  • National Medical Research Council Clinician Scientist Award (Investigator category), 2010
  • European Society of Cardiology Moderated Poster Award Winner, 2010
  • Evans Department of Medicine Research Days, Boston University School of Medicine, (3rd Prize for Clinical/Patient Based Research), 2009 
  • American Heart Association Women in Cardiology Trainee Award for Excellence, 2008
  • Jay N Cohn New Investigator Clinical/ Integrative Physiology Award Competition (First prize), 2006
  • Liew Weng Chee Scholarship, 2005
  • China Medical Board Scholarship, 2004
  • Singapore Cardiac Society Young Investigator Award (First prize), 2004

Research Interests

  • Heart failure with preserved ejection fraction
  • Women’s heart health
  • Cardiovascular clinical trials
  • Biomarkers

Publications and Research Trials

  • ​Multimorbidity in patients with heart failurefrom 11 Asian regions: A prospective cohort study using the ASIAN-HF registry. Jasper Tromp, Wan Ting Tay, Wouter Ouwerkerk, Tiew-Hwa Katherine Teng, Jonathan Yap, Michael R. MacDonald, Kirsten Leineweber, John J. V. McMurray, Michael R. Zile, Inder S. Anand, Carolyn S. P. Lam. PLOS Medicine 2018. JIF: 13.585
  • Lower Cardiovascular Risk Associated with SGLT-2i in More than 400,000 Patients: The CVD-REAL 2 Study. Mikhail Kosiborod, Carolyn S P Lam, Shun Kohsaka, Dae Jung Kim, Avraham Karasik, Jonathan Shaw, Navdeep Tangri, Su-Yen Goh, Marcus Thuresson, Hungta Chen, Filip Surmont, Niklas Hammar, Peter Fenici on behalf of the CVD-REAL Investigators and Study Group. Journal of the American College of Cardiology 2018. JIF: 19.896
  • Mortality Associated With Heart Failure With Preserved Versus Reduced Ejection Fracton In A Prospective International Multi-Ethnic Cohort Study. Carolyn S.P. Lam, Greg D Gamble, Lieng H. Ling, David Sim, Kui Toh Gerard Leong, Poh Shuan Daniel Yeo, Hean Yee Ong, Fazlur Jaufeerally, Tze P Ng, Vicky A Cameron, Katrina Poppe, Mayanna Lund, Gerry Devlin, Richard Troughton, A. Mark Richards*, Robert N Doughty *(*Co-senior authors). European Heart Journal 2018. JIF: 20.212
  • "The Soluble Guanylate Cyclase Stimulator Vericiguat in Worsening Chronic Heart Failure with Reduced Ejection Fraction". Mihai Gheorghiade; Stephen J Greene; Javed Butler; Gerasimos Filippatos; Carolyn S Lam; Aldo P Maggioni; Piotr Ponikowski; Sanjiv J Shah; Scott D Solomon; Elisabeth Kraigher-Krainer; Eliana T Samano; Katharina Müller Dipl; Lothar Roessig; Burkert Pieske; The SOCRATES-REDUCED Investigators and Coordinators. The SOCRATES-REDUCED Clinical Trial JAMA. 2015 Nov 8:1-13. doi: 10.1001/jama.2015.15734.
  • "Regional and ethnic differences among patients with heart failure in Asia: the Asian sudden cardiac death in heart failure registry". Carolyn S.P. Lam; Tiew-Hwa Katherine Teng; Wan Ting Tay; Inder Anand, Shu Zhang6,Wataru Shimizu7, Calambur Narasimhan8 SangWeon Park, Cheuk-Man Yu10, Tachapong Ngarmukos, Razali Omar12, Eugene B. Reyes, Bambang B. Siswanto14, Chung-Lieh Hung, Lieng H. Ling, Jonathan Yap, Michael MacDonald, and A. Mark Richards. European Heart Journal 2016 doi:10.1093/eurheartj/ehw331
  • "Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study". Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. J Am Coll Cardiol. 2009 Mar 31;53(13):1119-26. doi: 10.1016/j.jacc.2008.11.051.
  • "Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community". Lam CS; Lyass A; Kraigher-Krainer E; Massaro JM; Lee DS; Ho JE; Levy D, Redfield MM, Pieske BM; Benjamin EJ; Vasan RS. Circulation. 2011 Jul 5;124(1):24-30. doi: 10.1161/CIRCULATIONAHA.110.979203. Epub 2011 Jun 13. Erratum in: Circulation. 2011 Oct 25;124(17):e458.
  • "Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota". Lam CS; Roger VL, Rodeheffer RJ; Bursi F; Borlaug BA; Ommen S; Kass DA; Redfield MM. Circulation. 2007 Apr 17;115(15):1982-90. Epub 2007 Apr 2. Erratum in: Circulation. 2007 May 22;115(20):e535.

Research Trials

  • ​Programme Lead of the Asian neTwork for Translational Research and Cardiovascular Trials (ATTRaCT) – an A*STAR Biomedical Research Council-funded research platform
  • Principal investigator of an ongoing nation-wide heart failure study in Singapore (the Singapore Heart Failure Outcomes and Phenotypes [SHOP] study)
  • A multinational Asian study of heart failure across 11 Asian countries (Asian Sudden Cardiac Death in Heart Failure [ASIAN-HF] study)
  • Asian Diabetes Outcomes Prevention Trial (ADOPT)